$XBI News
Last published 5d ago
- 5d agoXBIMike Philbrick’s Top Picks for Nov. 6, 2026BNN BloombergTop Picks from Mike Philbrick, CEO, ReSolve Asset Management
- 1w agoGMABABBVMRKJNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- 3mo ago159892-CN9888-HKBIDUBABA+1Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong firstCNBCGlobal biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
- 4mo agoAZN-GBALNYXBIAstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?CNBCFor years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
- 4mo agoGSKNUVLXBIIBB+3Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBCCNBCBiopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
- 5mo agoLLYBMYMRKPFE+3The space race is coming for pharma: Why drug development is heading to lower Earth orbitCNBCCompanies see a commercial opportunity in creating new ways to administer drugs to patients – in space.
- 5mo agoXBIGSKLLY‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-CovidCNBCDriven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
- 1y agoMRNANVAXXBIVaccine stocks fall after key FDA official resigns in protest of RFK Jr.CNBCShares of Moderna, Novavax and other biotech companies fell after FDA official Peter Marks's resignation in protest of Robert F. Kennedy Jr.
- 1y agoIRDXBIShareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.GlobeNewswireCurrent Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months New Leadership is Urgently Needed to Restore Accountability in the Boardroom Restore Value
- 2y ago.SPXMRNAPFELLY+14Here are the big health sector themes to watch next yearCNBCThe health-care sector has seen a big rebound this month, and analysts say some beaten-down names will continue to have positive momentum in 2024.
- 2y agoIMGNABBVXBI.NBI+6Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billionCNBCOther biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.
- 5y agoXBIXLY.SPXDLTR+2These overlooked, 'Fed-proof' August laggards could be due for a bounceCNBCRetail could come back in a big way as back-to-school and holiday shopping return, two market analysts say.
- 6y agoAZN-GBXLVIBBXBI+4Health care has 'more room to run' after hitting record highs, ETF analyst saysCNBCThe health-care trade can continue to work as biotechnology and pharmaceutical companies get closer to finding treatments and a possible vaccine for Covid-19, says Todd Rosenbluth, senior director of ETF and mutual fund research at CFRA.
- 6y agoIBBXBIMissed the biotech breakout? These stocks in the industry are still set to run, MKM saysCNBCBiotechnology stocks have ripped higher in 2020 and some investors might have missed their chance to capitalize on the surge.
- 6y agoABBVXBIThis is AbbVie stock's key level after upgrade, says market analystCNBCIf AbbVie's stock can breach the $100 level, it could be off to the races, says Todd Gordon, managing director at Ascent Wealth Partners.
- 6y agoHOLXDGXINCYXLV+8Investor hope pushes biotech stocks to best monthly gain in two decadesCNBCStrong gains in April pushed the health care sector near year highs on hopes for new Covid treatments.